NO971256L - Påvisning og behandling av kreft - Google Patents

Påvisning og behandling av kreft

Info

Publication number
NO971256L
NO971256L NO971256A NO971256A NO971256L NO 971256 L NO971256 L NO 971256L NO 971256 A NO971256 A NO 971256A NO 971256 A NO971256 A NO 971256A NO 971256 L NO971256 L NO 971256L
Authority
NO
Norway
Prior art keywords
patient
afp
cancer cells
cancer
introducing
Prior art date
Application number
NO971256A
Other languages
English (en)
Other versions
NO323754B1 (no
NO971256D0 (no
Original Assignee
Moro Ricardo J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moro Ricardo J filed Critical Moro Ricardo J
Publication of NO971256L publication Critical patent/NO971256L/no
Publication of NO971256D0 publication Critical patent/NO971256D0/no
Publication of NO323754B1 publication Critical patent/NO323754B1/no

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5757Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncofoetal proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817Toxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/92Detection of biochemical

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO19971256A 1994-09-19 1997-03-18 Anvendelse av en sammensetning som omfatter anti-(alfa-fetoproteinreseptor)-antistoff til a femstille et farmasoytisk preparat til a behandle kreft NO323754B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30814194A 1994-09-19 1994-09-19
PCT/IB1995/000902 WO1996009551A1 (en) 1994-09-19 1995-09-18 Detection and treatment of cancer

Publications (3)

Publication Number Publication Date
NO971256L true NO971256L (no) 1997-03-18
NO971256D0 NO971256D0 (no) 1997-03-18
NO323754B1 NO323754B1 (no) 2007-07-02

Family

ID=23192727

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19971256A NO323754B1 (no) 1994-09-19 1997-03-18 Anvendelse av en sammensetning som omfatter anti-(alfa-fetoproteinreseptor)-antistoff til a femstille et farmasoytisk preparat til a behandle kreft

Country Status (15)

Country Link
US (1) US6514685B1 (no)
EP (3) EP0782709B1 (no)
KR (1) KR970706498A (no)
CN (2) CN1132012C (no)
AT (1) ATE449342T1 (no)
AU (1) AU714966B2 (no)
BR (1) BR9508959A (no)
CA (1) CA2197490A1 (no)
DE (1) DE69536019D1 (no)
DK (1) DK0782709T3 (no)
ES (1) ES2336976T3 (no)
FI (1) FI121353B (no)
NO (1) NO323754B1 (no)
RU (1) RU2161042C2 (no)
WO (1) WO1996009551A1 (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115399B2 (en) * 2001-07-31 2006-10-03 Allergan, Inc. Pinna reflex assay
AU2003216048A1 (en) * 2002-01-10 2003-07-30 David Kleinfeld Iterative optical based histology
CA2514058C (en) * 2003-01-24 2014-05-13 Agensys, Inc. Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer
CN100360684C (zh) * 2005-02-01 2008-01-09 合肥中科大生物技术有限公司 甲胎蛋白(AFP)mRNA荧光定量RT-PCR检测试剂盒
EP2952522B1 (en) 2007-01-31 2019-10-30 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
AU2008232709C1 (en) 2007-03-28 2015-01-15 President And Fellows Of Harvard College Stitched polypeptides
RU2377962C1 (ru) * 2008-06-10 2010-01-10 Государственное научное учреждение Всероссийский научно-исследовательский институт экспериментальной ветеринарии им. Я.Р. Коваленко РАСХН(ВИЭВ) Способ диагностики лейкоза крупного рогатого скота
BRPI0911925B8 (pt) 2008-08-05 2024-02-06 Toray Industries Método para detectar um câncer
KR101638490B1 (ko) 2008-08-05 2016-07-11 도레이 카부시키가이샤 암의 치료 및 예방용 의약 조성물
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
US9186128B2 (en) 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
US8968210B2 (en) * 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection
US20130072439A1 (en) 2009-09-22 2013-03-21 Huw M. Nash Peptidomimetic macrocycles
AU2010309438A1 (en) * 2009-10-22 2012-06-07 Ricardo J. Moro Peptides that bind the alpha-fetoprotein (AFP) receptor and uses thereof
BR112012018943A8 (pt) * 2010-02-04 2017-12-19 Toray Industries medicamento e método para o tratamento e/ou prevenção de um câncer
EP2889295A1 (en) 2010-08-12 2015-07-01 New York University Oligooxopiperazines and methods of making and using them
KR20170058446A (ko) 2010-08-13 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
BR112014002616B1 (pt) 2011-08-04 2022-01-18 Toray Industries, Inc Método para detectar câncer pancreático
AR088392A1 (es) 2011-10-18 2014-05-28 Aileron Therapeutics Inc Macrociclos peptidomimeticos
CA2862038C (en) 2012-02-15 2021-05-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CN104334541A (zh) 2012-02-16 2015-02-04 纽约大学 使用低聚氧代哌嗪非肽螺旋模拟物对低氧诱导基因表达的控制
RU2646466C2 (ru) 2012-07-19 2018-03-05 Торэй Индастриз, Инк. Метод детекции рака
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
ES2704909T3 (es) 2013-08-09 2019-03-20 Toray Industries Composición farmacéutica para el tratamiento y/o la prevención del cáncer
WO2016049359A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
SG11201702175YA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP2018528217A (ja) 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics,Inc. Mcl−1のモジュレーターとしてのペプチド模倣大環状分子
US11273151B2 (en) 2015-11-04 2022-03-15 Icahn School Of Medicine At Mount Sinai Methods of treating tumors and cancer, and identifying candidate subjects for such treatment
US11246868B2 (en) 2016-04-26 2022-02-15 Icahn School Of Medicine At Mount Sinai Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
CN106290876B (zh) * 2016-08-11 2018-06-29 湖南新大陆生物技术有限公司 一种肿瘤细胞检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2682697B2 (ja) 1989-03-29 1997-11-26 積水化学工業株式会社 免疫測定試薬および免疫測定法
FR2701710B1 (fr) * 1993-02-18 1995-04-21 Intromed Ltd Conjugués protéiques, compositions les contenant et leurs applications en tant que médicament et réactif de diagnostic.

Also Published As

Publication number Publication date
KR970706498A (ko) 1997-11-03
EP1956374A1 (en) 2008-08-13
EP0782709B1 (en) 2009-11-18
EP0782709A1 (en) 1997-07-09
US6514685B1 (en) 2003-02-04
BR9508959A (pt) 1997-12-30
CA2197490A1 (en) 1996-03-28
DE69536019D1 (de) 2009-12-31
AU3764895A (en) 1996-04-09
WO1996009551A1 (en) 1996-03-28
EP1955714A1 (en) 2008-08-13
RU2161042C2 (ru) 2000-12-27
FI121353B (fi) 2010-10-15
CN1169778A (zh) 1998-01-07
ES2336976T3 (es) 2010-04-19
NO323754B1 (no) 2007-07-02
AU714966B2 (en) 2000-01-13
CN1132012C (zh) 2003-12-24
CN100472213C (zh) 2009-03-25
CN1502994A (zh) 2004-06-09
FI970990A7 (fi) 1997-03-10
NO971256D0 (no) 1997-03-18
DK0782709T3 (da) 2010-03-29
FI970990A0 (fi) 1997-03-10
ATE449342T1 (de) 2009-12-15

Similar Documents

Publication Publication Date Title
NO971256L (no) Påvisning og behandling av kreft
DE69910007D1 (de) Vorrichtung zum vorhersagen von physiologischen messwerten
DK0943097T3 (da) Fremgangsmåde til at påvise IgE
NO904001D0 (no) Fremgangsmaate og anordning for amperometrisk diagnoseanalyse.
NO940901D0 (no) Gensöker-biosensor-metode
ATE200151T1 (de) Analytische testvorrichtung einschliesslich negativ- und positivkontrolle
DE68924779D1 (de) Vorrichtung und verfahren zum nachweis von chemischen spezies.
DK1141728T3 (da) Påvisning af nyresygdom og behandling deraf
ATE137583T1 (de) Verfahren und vorrichtung zur bestimmung von chemischen spezies in körperflüssigkeit
RU97106059A (ru) Обнаружение и лечение рака
DE3584796D1 (de) Verfahren und vorrichtung zur durchfuehrung analytischer bestimmungen.
HUP9701717A2 (hu) Eljárás cPSA-meghatározására
DE3684880D1 (de) Verfahren und apparat zur bestimmung des antikoerperinhalts von blut.
DE69504959D1 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
NZ332641A (en) method of detecting a lysosomal storage disorder by assaying the level of an enzyme, protein or peptide associated with the disease
DE3856004D1 (de) Verwendung von monoclonalen rezeptoren gegen oncoproteinen zur überwachung von krebstherapie
HUP9800225A2 (hu) Eljárás és vegyületek analitok meghatározására remanenciaméréssel és ezek alkalmazásai
EP0807689A4 (en) METHOD FOR DETECTING CELLS
DE69521145D1 (de) Verfahren zur kompetitiven bestimmung eines haptens
RU97100364A (ru) Способ для обнаружения и оценки концентрации анаэробных бактерий в биологическом субстрате
FI881521A7 (fi) Kontinuerlig oevervakningsanordning och -foerfarande foer faststaellande av graden av fullstaendighet av massakok.
ATE483734T1 (de) Vorrichtung und verfahren zur bestimmung des eintretens und vorhandenseins septischer bedingungen
ATE213835T1 (de) Verfahren zur bestimmung und zum nachweis von spenderorganschäden nach xenotransplantation auf der grundlage von aus dem spenderorgan freigesetzten analyten
Ottó Simple screening of Bence-Jones proteins from unconcentrated urine
ATE195183T1 (de) Methode zur bestimmung einer substanz

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees